Exomide, the next-generation exosome-led topical booster, has officially arrived in New Zealand clinics following strong momentum across leading Australian aesthetic practices.
Developed in South Korea, Exomide is a clinic-exclusive cosmeceutical recognised as one of the first exosome-based topical boosters of its kind available in the professional aesthetics market.
Exosomes are microscopic messengers involved in cellular communication within the skin. In cosmetic applications, they are used to support the skin’s natural processes, working in synergy with its existing functions rather than acting as a traditional surface-level ingredient.
Exomide combines a highly concentrated exosome formulation with carefully selected active ingredients designed for professional in-clinic use. It is typically incorporated into treatment protocols such as microneedling and energy-based procedures, where supporting skin health is a key focus.
Used as a topical booster, Exomide is designed to support visible improvements in skin quality over time, including refined texture, a more even-looking tone and enhanced radiance.
Its arrival in New Zealand reflects the continued shift towards regenerative, science-led skincare solutions that prioritise long-term skin health and quality over short-term correction. As demand grows for advanced clinical treatments, exosome-based technologies are increasingly being recognised as part of the next evolution in professional skincare.
Exomide is available exclusively through selected clinics across New Zealand. To find a clinic or learn more about adding Exomide to your clinic’s offering, visit exomide.co.nz or follow @exomide.anz on Instagram.
